RESUMEN
Various preclinical studies with developed Eustachian tube (ET) stents are in progress but have not yet been clinically applied. ET stent is limited by stent-induced tissue hyperplasia in preclinical studies. The effectiveness of sirolimus-eluting cobalt-chrome alloy stent (SES) in suppressing stent-induced tissue hyperplasia after stent placement in the porcine ET model was investigated. Six pigs were divided into two groups (i.e., the control and the SES groups) with three pigs for each group. The control group received an uncoated cobalt-chrome alloy stent (n = 6), and the SES group received a sirolimus-eluting cobalt-chrome alloy stent (n = 6). All groups were sacrificed 4 weeks after stent placement. Stent placement was successful in all ETs without procedure-related complications. None of the stents was able to keep its round shape as original, and mucus accumulation was observed inside and around the stent in both groups. On histologic analysis, the tissue hyperplasia area and the thickness of submucosal fibrosis were significantly lower in the SES group than in the control group. SES seems to be effective in suppressing stent-induced tissue hyperplasia in porcine ET. However, further investigation was required to verify the optimal stent materials and antiproliferative drugs.
Asunto(s)
Stents Liberadores de Fármacos , Trompa Auditiva , Animales , Aleaciones de Cromo , Cobalto , Stents Liberadores de Fármacos/efectos adversos , Trompa Auditiva/efectos de los fármacos , Trompa Auditiva/patología , Trompa Auditiva/cirugía , Hiperplasia/patología , Hiperplasia/prevención & control , Sirolimus/farmacología , Stents/efectos adversos , Porcinos , Resultado del TratamientoRESUMEN
OBJECTIVES: To evaluate histologic changes in middle ear and eustachian tube (ET) mucosa of mice after exposure to tobacco or electronic cigarette (e-cigarette) smoke. To determine whether there were any mitigating effects of middle ear application of anti-IL-13 or the epidermal growth factor receptor antagonist AG1478 on noted changes within ET mucosa. STUDY DESIGN: Controlled animal study. METHODS: Fifty BALB/cJ mice were randomly assigned to one of five groups: A control group with no smoke exposure, two groups exposed to tobacco smoke, and two groups exposed to e-cigarette vapor. Within the exposed groups after 4 weeks of exposure, one ear was infiltrated with a saline hydrogel and the other ear with hydrogel of either Anti-IL-13 or AG1478. After four more weeks of exposure, the animals were euthanized and the ETs were evaluated for mucosal changes. RESULTS: Compared to control animals with no smoke exposure, there were significant decreases in the numbers of goblet cells within the ET mucosa of mice exposed to tobacco smoke and e-cigarette vapor. No significant differences in cilia, mucin, or squamous metaplasia were noted. Neither anti-IL-13 nor AG178 significantly altered goblet cell count in the ET mucosa of mice exposed to tobacco smoke; however, both agents significantly increased goblet cells within the ET mucosa of mice exposed to e-cigarette vapor. CONCLUSION: Short-term tobacco smoke and e-cigarette vapor significantly decrease goblet cell count in mouse ET mucosa. Middle ear application of both anti-IL-13 and AG1478 resulted in an increase in goblet cell count among mice exposed to e-cigarette vapor, but not to tobacco smoke. LEVEL OF EVIDENCE: NA Laryngoscope, 132:648-654, 2022.
Asunto(s)
Cigarrillo Electrónico a Vapor/efectos adversos , Trompa Auditiva/efectos de los fármacos , Membrana Mucosa/efectos de los fármacos , Contaminación por Humo de Tabaco/efectos adversos , Animales , Sistemas Electrónicos de Liberación de Nicotina , Femenino , Células Caliciformes/efectos de los fármacos , Masculino , Ratones , Ratones Endogámicos BALB CRESUMEN
BACKGROUND: Topical nasal decongestants are frequently used as part of the medical management of symptoms related to Eustachian tube dysfunction. OBJECTIVE: This study aimed to assess the effect of topical xylometazoline hydrochloride sprayed in the anterior part of the nose on Eustachian tube active and passive opening in healthy ears. METHODS: Active and passive Eustachian tube function was assessed in healthy subjects before and after intranasal administration of xylometazoline spray, using tympanometry, video otoscopy, sonotubometry, tubo-tympano-aerodynamic-graphy and tubomanometry. RESULTS: Resting middle-ear pressures were not significantly different following decongestant application. Eustachian tube opening rate was not significantly different following the intervention, as measured by all function tests used. Sonotubometry data showed a significant increase in the duration of Eustachian tube opening following decongestant application. CONCLUSION: There remains little or no evidence that topical nasal decongestants improve Eustachian tube function. Sonotubometry findings do suggest that further investigation with an obstructive Eustachian tube dysfunction patient cohort is warranted.
Asunto(s)
Trompa Auditiva/fisiopatología , Pruebas Auditivas/métodos , Imidazoles/administración & dosificación , Descongestionantes Nasales/administración & dosificación , Pruebas de Impedancia Acústica , Administración Intranasal , Adulto , Estudios de Cohortes , Trompa Auditiva/efectos de los fármacos , Femenino , Voluntarios Sanos , Humanos , Imidazoles/farmacología , Masculino , Persona de Mediana Edad , Descongestionantes Nasales/farmacología , Grabación en Video , Adulto JovenRESUMEN
OBJECTIVE: To assess the effect of topical betahistine on Eustachian tube function in subjectively abnormal subjects in a hyperbaric chamber. METHOD: Active and passive Eustachian tube function was examined using tympanometry in a pressure chamber. RESULTS: Active Eustachian tube function was tested against the negative middle ear pressure induced by increasing the chamber pressure to +3 kPa. One voluntary swallow decreased middle-ear pressure by a mean of 1.36 kPa. Passive Eustachian tube function was tested by measuring spontaneous Eustachian tube openings as the chamber pressure dropped from +10 kPa to ambient. Four distinct patterns of Eustachian tube behaviour were seen, three of which indicated Eustachian tube dysfunction. Betahistine had no positive effect on Eustachian tube opening, although previous animal studies had suggested a beneficial effect. CONCLUSION: Topical betahistine had no effect on Eustachian tube function. Combining a hyperbaric chamber with tympanometry proved ideal for evaluating Eustachian tube function.
Asunto(s)
Pruebas de Impedancia Acústica/métodos , Betahistina/administración & dosificación , Trompa Auditiva/fisiopatología , Administración Intranasal , Adulto , Cámaras de Exposición Atmosférica , Betahistina/farmacología , Técnicas de Diagnóstico Otológico , Trompa Auditiva/efectos de los fármacos , Femenino , Humanos , Masculino , Persona de Mediana Edad , Adulto JovenAsunto(s)
Trastornos Relacionados con Cocaína/patología , Cocaína/toxicidad , Enfermedades del Oído/patología , Trompa Auditiva/patología , Drogas Ilícitas/toxicidad , Adulto , Trastornos Relacionados con Cocaína/diagnóstico , Enfermedades del Oído/inducido químicamente , Enfermedades del Oído/diagnóstico , Trompa Auditiva/efectos de los fármacos , Femenino , HumanosRESUMEN
OBJECTIVES: To describe the association between active, environmental tobacco smoke (ETS) exposure and the prevalence of eustachian tube dysfunction (ETD) in the U.S. pediatric population. STUDY DESIGN: Cross-sectional. SETTING: U.S. representative demographic and audiometric data from the National Health and Nutrition Examination Survey (NHANES);2005-2010. SUBJECTS AND METHODS: The study consisted of 2,977 children aged 12-19 years. ETD was defined as middle ear pressure <100mm H20. ETS was defined as non-active smoking in individuals with serum cotinine over the limit of detection (≥0.015 ng/mL) and <10 ng/mL(N = 1559). RESULTS: The prevalence of ETD was 6.1%. After multivariate adjustment for age, sex, body mass index, education level, ethnicity, or having a cold, sinus problem or earache during the last 24 hours, compared to unexposed children, the odds ratios (95% confidence interval) of ETD for those exposed to ETS ages 12-15 in the first, second and third tertile of cotinine concentrations were, respectively, 1.38 (0.53-3.60), 0.99 (0.53-3.60) and 2.67 (1.12-6.34). Similarly, the odds ratios (95% confidence interval) of ETD for those exposed to ETS ages 16-19 in the first, second and third tertile of cotinine concentrations were, respectively, 1.28 (0.48-3.41), 0.99 (0.40-2.48) and 2.86 (1.19-6.88). CONCLUSION: These data suggest that children and adolescents exposed to high concentrations of ETS may have an increased prevalence of ETD.
Asunto(s)
Exposición a Riesgos Ambientales/efectos adversos , Trompa Auditiva/efectos de los fármacos , Trompa Auditiva/fisiopatología , Humo/efectos adversos , Pruebas de Impedancia Acústica , Adolescente , Niño , Cotinina/sangre , Femenino , Humanos , Masculino , Presión , Encuestas y Cuestionarios , Nicotiana/química , Estados Unidos , Adulto JovenRESUMEN
OBJECTIVE: The most common complications of hyperbaric oxygen treatment (HBOT) are related to pressure changes on gas-containing cavities. Therefore, inability to auto-inflate the middle ear may result in transient or permanent hearing loss. However, it seems that middle ear barotrauma (MEBt) does not develop more often in mechanically ventilated patients than in ambulatory patients. This might be explained by deep sedation of these patients. Therefore, the aim of this study was to determine whether anaesthesia and/or neuromuscular blockade can influence Eustachian tube (ET) function. METHODS: Forty patients who were undergoing surgery under general anaesthesia were enrolled in this prospective study. ET function was evaluated by tympanography performed three times: before induction of general anaesthesia (baseline), after induction with sufentanyl/propofol and after full blockade was achieved with a long-acting neuromuscular blocking agent. RESULTS: There were no differences in ear volume (P = 0.19) and ear pressure (P = 0.07). There was a significant variation in compliance on tympanography after the induction of general anaesthesia (P = 0.009). Compared to the baseline, this variation was characterized by an increase after induction of anaesthesia (24 ± 7.13%, P ã 0.01) and neuromuscular blockade (23 ± 8.9%, P ã 0.05). The difference between after induction and after neuromuscular blockade was not statistically significant (P = 0.13). DISCUSSION: The findings of this trial suggest that the administration of hypnotic drugs associated with opioids improves ET compliance. Therefore it may have favourable prophylactic effects on MEBt in ventilated intensive care unit patients scheduled for HBOT.
Asunto(s)
Analgésicos Opioides/farmacología , Anestesia General , Anestésicos/farmacología , Trompa Auditiva/efectos de los fármacos , Bloqueo Neuromuscular , Bloqueantes Neuromusculares/farmacología , Pruebas de Impedancia Acústica/métodos , Atracurio/farmacología , Trompa Auditiva/fisiología , Humanos , Oxigenoterapia Hiperbárica , Propofol/farmacología , Estudios Prospectivos , Estadísticas no Paramétricas , Sufentanilo/farmacología , Procedimientos Quirúrgicos OperativosRESUMEN
BACKGROUND: Balloon Eustachian Tuboplasty (BET) is a new minimally invasive treatment for chronic Eustachian tube dysfunction (ETD). Initially, perioperative prophylactic antibiotic therapy with ciprofloxacin 2 × 500 mg p.o. for 5 days was administered. This study aimed to characterize the bacterial flora in the ET, nose, and pharynx in patients with chronic obstructive ETD. Additionally, we investigated the necessity of perioperative antibiotic prophylaxis in BET patients. PATIENTS AND METHODS: We examined 40 patients undergoing BET: 20 patients with and 20 patients without perioperative antibiotic prophylaxis. All patients were followed-up for clinical signs and symptoms of local infection for at least 2 weeks after surgery. Following BET, the tips of 35 balloon catheters, as well as swabs from the nose and pharynx were sent for microbiologic analysis. RESULTS: None of these 40 patients had postoperative signs of infection. Of the swabs of the balloon catheters, 46% were sterile and 23% showed standard flora. The remaining 31% of swaps revealed specific bacteria. However, none of the nasal or nasopharyngeal swaps were sterile. CONCLUSION: Due to the lack of signs of postoperative infection in either investigated group, the authors no longer favor use of perioperative antibiotic prophylaxis in patients undergoing BET. The relevance of biofilms and pathogen colonization to ET function has recently been intensively discussed, and should be further investigated in future studies.
Asunto(s)
Profilaxis Antibiótica/métodos , Infecciones Bacterianas/etiología , Infecciones Bacterianas/prevención & control , Ventilación del Oído Medio/efectos adversos , Infección de la Herida Quirúrgica/etiología , Infección de la Herida Quirúrgica/prevención & control , Antibacterianos/uso terapéutico , Infecciones Bacterianas/microbiología , Ciprofloxacina/uso terapéutico , Trompa Auditiva/efectos de los fármacos , Trompa Auditiva/microbiología , Humanos , Ventilación del Oído Medio/instrumentación , Ventilación del Oído Medio/métodos , Atención Perioperativa/métodos , Infección de la Herida Quirúrgica/microbiología , Resultado del TratamientoRESUMEN
The objective of the present study was to estimate the clinical effectiveness of fenspiride used to correct the obstruction of the Eustachian tube in 80 patients presenting with acute tubootitis and exudative otitis media. The algorithm of the examination included the evaluation of the severity of subjective clinical symptoms based on the relevant analog-visual scale, results of tonal audiometry, and tympanometry. The control group was comprised of 34 patients treated with antibacterial preparations, topical decongestants, and transtubal administration of glucocorticoids. The study group included 46 patients who received fenspiride at a dose of 80 mg thrice daily in addition to the above pharmacotherapy. The severity of clinical symptoms in the patients treated with fenspiride decreased faster than in the control subjects. The frequency analysis of dynamics of the air-bone gaps on the audiometric curves revealed the significantly more intensive recovery of the hearing function in the patients treated by basal pharmacotherapy in the combination with fenspiride. Type A tympanograms predominated on day 7 after the onset of the conservative treatment with the use of fenspiride whereas type C tympanograms continued to predominate in the patients of the control group. It is concluded that the introduction of fenspiride into combined therapy of acute tubootitis and exudative otitis media promotes the normalization of the ventilation and drainage functions and relieves the severity of subjective clinical symptoms.
Asunto(s)
Broncodilatadores/farmacología , Trompa Auditiva , Otitis , Compuestos de Espiro/farmacología , Adulto , Trompa Auditiva/efectos de los fármacos , Trompa Auditiva/patología , Trompa Auditiva/fisiopatología , Femenino , Humanos , Masculino , Persona de Mediana Edad , Otitis/complicaciones , Otitis/tratamiento farmacológico , Otitis/fisiopatología , Resultado del TratamientoRESUMEN
We aim to explore the role of epidermal growth factor (EGF) ligand shedding in tympanic membrane wound healing and to investigate the translation of its modulation in tissue engineering of chronic tympanic membrane perforations. Chronic suppurative otitis media (CSOM) is an infected chronic tympanic membrane perforation. Up to 200 million suffer from its associated hearing loss and it is the most common cause of pediatric hearing loss in developing countries. There is a need for nonsurgical treatment due to a worldwide lack of resources. In this study, we show that EGF ligand shedding is essential for tympanic membrane healing as it's inhibition, with KB-R7785, leads to chronic perforation in 87.9% (n=58) compared with 0% (n=20) of controls. We then show that heparin binding-EGF-like growth factor (5 µg/mL), which acts to shed EGF ligands, can regenerate chronic perforations in mouse models with 92% (22 of 24) compared with 38% (10 of 26), also with eustachian tube occlusion with 94% (18 of 19) compared with 9% (2 of 23) and with CSOM 100% (16 of 16) compared with 41% (7 of 17). We also show the nonototoxicity of this treatment and its hydrogel delivery vehicle. This provides preliminary data for a clinical trial where it could be delivered by nonspecialist trained healthcare workers and fulfill the clinical need for a nonsurgical treatment for chronic tympanic membrane perforation and CSOM.
Asunto(s)
Factor de Crecimiento Similar a EGF de Unión a Heparina/uso terapéutico , Regeneración/efectos de los fármacos , Perforación de la Membrana Timpánica/tratamiento farmacológico , Perforación de la Membrana Timpánica/fisiopatología , Animales , Materiales Biocompatibles/química , Enfermedad Crónica , Modelos Animales de Enfermedad , Sistemas de Liberación de Medicamentos , Receptores ErbB/metabolismo , Trompa Auditiva/efectos de los fármacos , Trompa Auditiva/patología , Trompa Auditiva/fisiopatología , Potenciales Evocados Auditivos del Tronco Encefálico/efectos de los fármacos , Glicina/análogos & derivados , Factor de Crecimiento Similar a EGF de Unión a Heparina/farmacología , Ácidos Hidroxámicos , Ligandos , Masculino , Ratones , Otitis Media Supurativa/tratamiento farmacológico , Otitis Media Supurativa/patología , Otitis Media Supurativa/fisiopatología , Emisiones Otoacústicas Espontáneas/efectos de los fármacos , Polímeros/química , Perforación de la Membrana Timpánica/patologíaRESUMEN
INTRODUCTION: The use of decongestants is common in otitis media eustachian tube (ET) dysfunction. However, the underlying mechanism and the type of action on the complex middle ear pressure equalization system are poorly understood. Here, by use of the pressure chamber, we investigated the impact of intranasal decongestive therapy (xylomethazoline) on ET function. MATERIALS AND METHODS: Thirty healthy participants (60 ears) were exposed to a predetermined profile of phases of compression and decompression in a hypobaric and hyperbaric pressure chamber. ET opening pressure, ET opening duration, ET opening frequency, and ET closing pressure were determined before and after intranasal application of xylomethazoline. RESULTS: A significantly higher number of ET openings (ET opening frequency) in passive equalization condition could be measured after application of decongestants than before. No significant difference could be found in the values of ET opening pressure, ET opening duration, and ET closing pressure parameters before in comparison with the values after application of xylomethazoline. CONCLUSION: We conclude that xylomethazoline might only have a minor effect during active and passive middle ear pressure equalization. Larger cohorts and targeted application of decongestants should be tested to confirm these preliminary data and to find new evidence on the effects of decongestants.
Asunto(s)
Trompa Auditiva/efectos de los fármacos , Imidazoles/administración & dosificación , Descongestionantes Nasales/administración & dosificación , Administración Intranasal , Adulto , Femenino , Voluntarios Sanos , Humanos , Masculino , Presión , Adulto JovenRESUMEN
OBJECTIVE: To evaluate the effect of nasal decongestants on eustachian tube (ET) opening. STUDY DESIGN: A prospective nonrandomized study. SETTING: A tertiary referral center. PATIENTS: Twenty-four patients (44 ears) with intact eardrums, 39 patients (43 ears) having a noninfected eardrum defect, and six patients with an upper airway infection. INTERVENTIONS: Nasal or intratympanal (in perforated ears) application of a nasal decongestant (xylometazoline 0.1%). MAIN OUTCOME MEASURES: Change of tube opening quality (yes or no; better or worse) measuring tube opening parameters (pressure, latency) using the Estève method and pressure equalization tests (swallowing at negative and positive external ear canal pressures). RESULTS: In most cases, nasal decongestion or intratympanal use of decongestants have no effect on ET opening. Improvement in tube opening is rather an exception and, in a minority of patients, a reduced ET function was evident. CONCLUSION: Our acute studies revealed no improvement in eustachian ventilatory tube function with the administration of nasal decongestants.
Asunto(s)
Trompa Auditiva/efectos de los fármacos , Imidazoles/administración & dosificación , Descongestionantes Nasales/administración & dosificación , Administración Intranasal , Humanos , Estudios Prospectivos , Infecciones del Sistema Respiratorio/tratamiento farmacológico , Membrana Timpánica/efectos de los fármacosRESUMEN
BACKGROUND: Eustachian tube dysfunction (ETD) is the inability of the Eustachian tube (ET) to adequately perform at least one of its functions: to protect the middle ear from sources of disease, to ventilate the middle ear, and to help drain secretions away from the middle ear. There are a number of treatment options for ETD, but there is little consensus about management. OBJECTIVES: To determine the clinical effectiveness of interventions for adult ETD and to identify gaps in the evidence to inform future research. DATA SOURCES: Twelve databases were searched up to October 2012 for published and unpublished studies in English (e.g. MEDLINE from 1946, EMBASE from 1974, Biosis Previews from 1969 and Cumulative Index to Nursing and Allied Health Literature from inception). References of included studies, relevant systematic reviews and regulatory agency websites were checked. REVIEW METHODS: A systematic review was undertaken. Controlled studies evaluating prespecified treatments for adult patients diagnosed with ETD were eligible. Uncontrolled studies with at least 10 participants were included for interventions where no controlled studies were found. Outcomes included change in symptoms severity/frequency (primary outcome), quality of life, middle ear function, hearing, clearance of middle ear effusion, early ventilation tube extrusion, additional treatment, adverse events and complications. All aspects of the review process were performed using methods to reduce reviewer error and bias. Owing to heterogeneous data, a quantitative synthesis could not be performed, and results were reported in a narrative synthesis. RESULTS: Nineteen studies were included: three randomised controlled trials (RCTs) and two non-RCTs evaluating pharmacological interventions or mechanical devices for middle ear pressure equalisation; and 13 case series and one retrospective controlled before-and-after study evaluating surgical interventions. None was conducted in the UK. All studies were small (11 to 108 participants). Most non-surgical studies reported including mixed populations of adults and children. All except two studies were at high risk of bias, and subject to multiple limitations. Based on a single RCT, nasal steroids showed no improvement in symptoms or middle ear function for patients with otitis media with effusion and/or negative middle ear pressure. Very short-term improvements in middle ear function were observed in patients receiving directly applied topical decongestants or a combination of antihistamine and ephedrine. Single trials found two pressure equalisation devices were each associated with significant short-term improvements in symptoms, middle ear function and/or hearing. Eustachian tuboplasty (seven case series) and balloon dilatation (three case series) were associated with improved outcomes. Positive results were also reported for myringotomy (two case series), directly applied topical steroids (one case series) and laser point coagulation (one controlled before-and-after study). High rates of co-interventions were documented. Minor complications of surgery and pharmacological treatments but no serious adverse effects were reported. LIMITATIONS: The evidence was limited in quantity and overall was of poor quality. No data were identified on several interventions despite extensive searches. CONCLUSIONS: It is not possible to draw conclusions regarding the effectiveness of any of the interventions for the treatment of adults with an ETD diagnosis, and there is insufficient evidence to recommend a trial of any particular intervention. Further research is needed to address lack of consensus on several issues, including the definition of ETD in adults, its relation to broader middle ear ventilation problems and clear diagnostic criteria. STUDY REGISTRATION: This study is registered as PROSPERO CRD42012003035. FUNDING: The National Institute for Health Research Health Technology Assessment programme.
Asunto(s)
Trompa Auditiva/fisiopatología , Ventilación del Oído Medio/métodos , Otitis Media con Derrame/tratamiento farmacológico , Otitis Media con Derrame/cirugía , Administración Tópica , Adulto , Antibacterianos/uso terapéutico , Ensayos Clínicos Controlados como Asunto , Trompa Auditiva/efectos de los fármacos , Trompa Auditiva/cirugía , Femenino , Antagonistas de los Receptores Histamínicos/uso terapéutico , Humanos , Masculino , Ventilación del Oído Medio/efectos adversos , Descongestionantes Nasales/uso terapéutico , Otitis Media con Derrame/diagnóstico , Pronóstico , Ensayos Clínicos Controlados Aleatorios como Asunto , Medición de Riesgo , Índice de Severidad de la Enfermedad , Resultado del TratamientoRESUMEN
OBJECTIVES/HYPOTHESIS: To evaluate the histopathological effect of intranasal pulmonary surfactant (PS) on the eustachian tube (ET) in guinea pigs with otitis media with effusion (OME). STUDY DESIGN: Randomized control trial. METHODS: Nonviable heat-killed Hemophilus influenzae solution was injected into the tympanum of guinea pigs by a trans-eardrum approach to establish OME. Guinea pigs were divided into four groups: normal controls (group A), untreated OME (group B), saline-treated (group C), PS-treated (group D). The response threshold of the guinea pigs was measured by auditory brainstem response (ABR), and data were analyzed by one-way analysis of variance. The histopathological changes in the osseous, cartilaginous, and muscular portions of the ET were observed systematically by light microscopy. RESULTS: The ABR threshold in OME group B was raised significantly compared with normal group (A). The response in saline-treated group C was not statistically significantly different compared with OME group B. Seven days after intranasal dripping of pulmonary surfactant in PS-treated group D, the response threshold showed at statistically significant decrease compared with OME B and saline-treated C groups. In OME group B and saline-treated group C, mucosa showed swelling with goblet cell hyperplasia, and cilia were irregularly arranged. In PS-treated group D, there was slight mucosal swelling with fewer goblet cells, and cilia were regularly arranged, similar to the normal group A. CONCLUSIONS: The findings of the study indicate that intranasal pulmonary surfactant drops have protective and hyposecretory effects on the mucociliary system of the ET in guinea pigs suffering from OME.
Asunto(s)
Oído Interno/patología , Trompa Auditiva/patología , Potenciales Evocados Auditivos del Tronco Encefálico/efectos de los fármacos , Otitis Media con Derrame/patología , Surfactantes Pulmonares/efectos adversos , Administración Intranasal , Animales , Modelos Animales de Enfermedad , Oído Interno/efectos de los fármacos , Trompa Auditiva/efectos de los fármacos , Cobayas , Otitis Media con Derrame/inducido químicamente , Otitis Media con Derrame/fisiopatología , Otoscopía , Surfactantes Pulmonares/administración & dosificaciónRESUMEN
We selected once more from about 15000 abstracts published in 2011 a couple of papers focused on general practice. Regarding the ear, we will discuss the role of nasal corticoids in Eustachian tube dysfunction, the treatment of vestibular neuronitis, the role of the bone-anchored hearing aid, or the vestibular implant. Regarding the nose, the influence of tobacco on sinus surgery, the treatment of staphylococcus cases, and the role of neuronavigation. Regarding the throat, head and neck region, our focus was on potential new treatments of the future that might change our approach, and on the correlations between food and cancer.
Asunto(s)
Medicina General , Enfermedades Otorrinolaringológicas/etiología , Enfermedades Otorrinolaringológicas/terapia , Corticoesteroides/uso terapéutico , Antibacterianos/uso terapéutico , Enfermedad Crónica , Sordera/terapia , Enfermedades del Oído/microbiología , Enfermedades del Oído/terapia , Trompa Auditiva/efectos de los fármacos , Audífonos , Humanos , Apófisis Mastoides/cirugía , Enfermedades Otorrinolaringológicas/diagnóstico , Enfermedades Otorrinolaringológicas/rehabilitación , Diseño de Prótesis , Implantación de Prótesis/métodos , Factores de Riesgo , Sinusitis/diagnóstico , Sinusitis/microbiología , Sinusitis/cirugía , Fumar/efectos adversos , Infecciones Estafilocócicas/diagnóstico , Infecciones Estafilocócicas/cirugía , Resultado del Tratamiento , Neuronitis Vestibular/terapiaRESUMEN
OBJECTIVE: Tympanostomy tube otorrhea (TTO), caused by the presence of pathogenic bacteria in the middle ear, is the most common complication of TT insertion. No studies have described a reproducible animal model of TTO. We aimed to develop a rat model of TTO which, in turn, could be used to assay the levels of TNF-α and IL-1ß through the course of the infection. METHODS: The left Eustachian tubes of 55 male Sprague-Dawley albino rats were occluded with gutta-percha (ETO=Eustachian Tube Occlusion). Middle ear (ME) effusion was ascertained by weekly otomicroscopy. At 3 weeks tympanostomy tubes were placed bilaterally and the MEs were inoculated bilaterally with Streptococcus pneumoniae through the tubes. The rats were randomly assigned to one of two daily ototopical treatments: ciprofloxacin/dexamethasone (CDX) or placebo. The animals in each of the two treatment groups were further divided to receive 1, 2, 5 or 7 days of treatment. The rats were sacrificed after treatment was finished. The rates of otorrhea, positive middle ear (ME) cultures, and levels of TNF-α and IL-1ß in the ME fluid were measured. RESULTS: Left ETO followed by ME inoculation with S. pneumoniae and treatment with placebo resulted in persistent infection (100% culture-positive ME fluid at 10 days) and otorrhea (85.7%). Persistent infection of the left ear was accompanied by significantly elevated the levels of IL-1ß and TNF-α. Ears treated with CDX had lower rates of otorrhea at all time points and lower levels of IL-1ß and TNF-α. CONCLUSIONS: This study is the first to describe a reproducible animal model of acute TTO. Surgical obstruction of the ET, followed by TT placement and ME inoculation with S. pneumoniae induced persistent otorrhea and infection. Both IL-1ß and TNF-α appear to be potential markers of persistent middle ear infection. This novel model may be used in future studies of the pathogenesis and therapy of TTO.
Asunto(s)
Antiinfecciosos/uso terapéutico , Ciprofloxacina/uso terapéutico , Dexametasona/uso terapéutico , Modelos Animales de Enfermedad , Ventilación del Oído Medio/efectos adversos , Otitis Media con Derrame/tratamiento farmacológico , Animales , Citocinas/metabolismo , Trompa Auditiva/efectos de los fármacos , Trompa Auditiva/cirugía , Mediadores de Inflamación/metabolismo , Interleucina-1beta/metabolismo , Masculino , Ventilación del Oído Medio/métodos , Otitis Media con Derrame/etiología , Distribución Aleatoria , Ratas , Ratas Sprague-Dawley , Valores de Referencia , Factores de Riesgo , Índice de Severidad de la Enfermedad , Resultado del Tratamiento , Factor de Necrosis Tumoral alfa/metabolismoRESUMEN
OBJECTIVE: To evaluate the utility of fluorescence to assess penetration of quinolone ear drops (EDs) through tympanostomy tubes (TTs), the middle ear, eustachian tube, and into the oropharynx. DESIGN: Before-and-after trial. SETTING: Academic, tertiary care hospital. PATIENTS: Young children undergoing TT placement for otitis media and adolescents or adults undergoing repair of tympanic membrane (TM) perforations were included. INTERVENTIONS: Fluorescence of ofloxacin otic solution and serial dilutions was assessed with a Wood's lamp in vitro. Passage of ototopically administered ofloxacin into the pharynx was assessed in patients at the time of TT placement or TM repair. The oropharynx was visualized for fluorescence with a UV light for up to 2 hours after otic instillation. MAIN OUTCOME MEASURE: Oropharyngeal fluorescence. RESULTS: Ofloxacin otic fluorescence was visible at up to a 1:4 dilution. Fluorescence was confirmed in vivo by placing 1 drop of ofloxacin into the posterior pharynx and visualizing it transorally. Fluorescence was not identified in any of 20 patients after TT placement and in any of 6 patients prior to tympanoplasty. Two patients undergoing tympanoplasty reported tasting the EDs. CONCLUSION: Fluorescence is not a satisfactory method of assessing quinolone ED penetration through TTs and TM perforations, the middle ear, and into the nasopharynx.
Asunto(s)
Antibacterianos/farmacocinética , Oído Medio/efectos de los fármacos , Oído Medio/metabolismo , Fluoroquinolonas/farmacocinética , Ventilación del Oído Medio , Miringoplastia , Ofloxacino/farmacocinética , Adolescente , Adulto , Antibacterianos/administración & dosificación , Disponibilidad Biológica , Niño , Preescolar , Relación Dosis-Respuesta a Droga , Trompa Auditiva/efectos de los fármacos , Trompa Auditiva/metabolismo , Femenino , Fluorescencia , Fluoroquinolonas/administración & dosificación , Hospitales Universitarios , Humanos , Masculino , Ofloxacino/administración & dosificación , Orofaringe/efectos de los fármacos , Orofaringe/metabolismo , Valor Predictivo de las Pruebas , Adulto JovenRESUMEN
CONCLUSION: Betahistine dihydrochloride, a drug used widely in the systemic treatment of balance disorders such as Ménière's disease, was found to improve eustachian tube function when applied topically in the nasopharynx of rats. OBJECTIVES: The study tested the effect of betahistine, a histamine receptor agonist, on eustachian tube function and tested the involvement of H1 and H3 histamine receptors. METHODS: Eustachian tube function was measured in anaesthetized rats while middle ear pressure was increased and then monitored during induced swallowing. Betahistine and other drugs were applied topically in the nasopharynx, bulla and epipharynx, and administered intraperitoneally. RESULTS: Systemic application of betahistine hardly changed eustachian tube function, but topical application significantly improved it. The action of topical betahistine was unaffected by the HI receptor antagonist mepyramine and was mimicked by the H3 agonist, ciproxifan.
Asunto(s)
Betahistina/administración & dosificación , Trompa Auditiva/efectos de los fármacos , Agonistas de los Receptores Histamínicos/administración & dosificación , Administración Tópica , Animales , Barotrauma/tratamiento farmacológico , Evaluación Preclínica de Medicamentos , Masculino , Enfermedad de Meniere/tratamiento farmacológico , Otitis Media/tratamiento farmacológico , Ratas , Ratas Sprague-Dawley , Receptores Histamínicos/metabolismoRESUMEN
OBJECTIVE: To determine the efficacy of intranasal aqueous triamcinolone acetonide in treating the tympanometric signs and symptoms of eustachian tube dysfunction, such as otitis media with effusion and negative middle ear pressure. DESIGN: Randomized, placebo-controlled, double-blind prospective clinical trial. SETTING: Tertiary referral clinic. PATIENTS: Adults (≥18 years) and children (6-17 years) presenting with otitis media with effusion, negative middle ear pressure, or both. INTERVENTIONS: The 2 treatment arms consisted of aqueous triamcinolone or matching placebo administered once daily intranasally for 6 weeks. All subjects underwent tympanometry, otologic examination, and completion of a symptom questionnaire before and after treatment. MAIN OUTCOME MEASURES: Resolution of abnormal tympanometry and change in symptom scores (severity and frequency). RESULTS: Ninety-one patients presenting from September 1, 2005, through December 31, 2008, with otitis media with effusion or with negative middle ear pressure were enrolled and randomly assigned to treatment or placebo in a double-blind manner. No statistically significant difference in normalization of abnormal tympanometric signs was demonstrated with the active treatment arm compared with placebo on either a per-patient basis (19% vs 32%; P = .18) or a per-ear basis (22% vs 35%; P = .15). There was also no significant difference in the overall poststudy symptom score between the 2 treatment arms, after adjusting for the prestudy overall symptom score in an analysis of covariance model (P = .27). CONCLUSION: These findings do not support the use of intranasal steroid sprays to treat the manifestations of eustachian tube dysfunction. Trial Registration clinicaltrials.gov Identifier: NCT00279916.
Asunto(s)
Trompa Auditiva/efectos de los fármacos , Trompa Auditiva/fisiopatología , Glucocorticoides/uso terapéutico , Rociadores Nasales , Otitis Media con Derrame/tratamiento farmacológico , Triamcinolona Acetonida/uso terapéutico , Adolescente , Adulto , Distribución de Chi-Cuadrado , Niño , Método Doble Ciego , Femenino , Glucocorticoides/administración & dosificación , Humanos , Modelos Logísticos , Masculino , Otitis Media con Derrame/fisiopatología , Placebos , Estudios Prospectivos , Estadísticas no Paramétricas , Encuestas y Cuestionarios , Resultado del Tratamiento , Triamcinolona Acetonida/administración & dosificaciónRESUMEN
BACKGROUND: Patulous eustachian tube (PET) has a major impact on a patient's quality of life. The purpose of this study was to understand mechanisms behind the symptoms, develop treatments based on these, and develop and use a questionnaire to measure changes in PET symptoms with a novel intervention. Our hypothesis is that PET symptoms can be addressed at the level of the eardrum more easily than at the level of the eustachian tube. METHODS: In a population of 14 PET subjects and 6 fresh temporal bones, several investigations were performed. Nasal audiometry was used to measure frequencies preferentially transmitted to the ear in PET subjects. An intervention consisting of mass loading of the eardrum was devised in the temporal bones to damp these frequencies. This was then applied to subjects with PET. A questionnaire was developed and administered to measure the response to this intervention. This questionnaire included the more common symptoms associated with PET, such as echoing sounds, increased environmental sounds, and a plugging sensation in the ear. Mass loading of the eardrum was performed with Blu Tack, a clay-like, nontoxic substance. RESULTS/CONCLUSION: Low frequencies are preferentially transmitted in PET, and eardrum vibrations to these can be mitigated with mass loading. Mass loading in human subjects significantly reduced major symptoms of PET, although temporarily.